This site is intended only for UK healthcare professionals

Welcome to the talking tough gram-negatives webinar series

To coincide with Shionogi B.V’s continued promotional activities following the launch of cefiderocol▼, this rolling webinar series aims to bring together medical professionals across the UK to discuss current issues surrounding multidrug-resistant Gram-negative infections. Each webinar is aimed at healthcare professionals with an interest in antimicrobial therapy and infectious diseases.

These webinars are organised and funded by Shionogi B.V. Prescribing information can be found underneath the meeting information, whilst adverse event reporting can be found at the bottom of the page.

Upcoming Webinars

Past Webinars

23 September 2021, 1700 - 1830

Multidrug-resistant gram-negative infections

FETCROJA ® (cefiderocol)

Metallo-β-lactamases and understanding minimum inhibitory concentrations

Dr Sara Boyd and Stephen Hughes will both be delivering a presentation focusing on current challenges surrounding Metallo-β-lactamases and minimum inhibitory concentrations. Infection control surrounding MBLs will be discussed, including why they are a problem and the different treatment options currently available. Both presentations will be immediately followed by a question and answer session. This webinar is accredited for 1 CPD point by The Royal College of Pathologists.

  • Dr Sara Boyd
    Specialist Registrar in Infectious Diseases & Microbiology, Chelsea and Westminster Hospital NHS Foundation Trust
  • Stephen Hughes
    Consultant Antimicrobial Pharmacist, Chelsea and Westminster Hospital NHS Foundation Trust

Duration

1 Hr 30

FETCROJA ® (cefiderocol) Prescribing Information
Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents¹

22 July 2021, 1700 - 1830

Multidrug-resistant gram-negative infections

FETCROJA ® (cefiderocol)

Antimicrobial Susceptibility Testing

Dr Mandy Wootton and Dr Nitin Mahobia both delivered a presentation surrounding antimicrobial susceptibility testing. Dr Wootton focused on global issues surrounding AST and discussing practical solutions, whilst Dr Mahobia spoke about AST research currently happening at Southampton, including testing for cefiderocol and an exciting new open access AST service. Both presentations were followed by a Q&A session. This webinar is accredited for 1 CPD point by The Royal College of Pathologists.

  • Dr Mandy Wootton
    Consultant Scientist, Specialist Antimicrobial Chemotherapy Unit, Public Health Wales
  • Dr Nitin Mahobia
    Consultant Medical Microbiologist, University Hospital Southampton NHS Foundation Trust

Duration

1 Hr 30

FETCROJA ® (cefiderocol) Prescribing Information
Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents¹

18 June 2021, 1700 - 1830

Multidrug-resistant gram-negative infections

FETCROJA ® (cefiderocol)

Cefiderocol early UK experience: Real-world examples from three UK centres

Dr David Jenkins, Dr Duncan Wyncoll and Alastair Bovell each delivered a 10 minute presentation on a real world case-study where cefiderocol was used. To watch the presentation recordings, please click the button below.

  • Dr David Jenkins
    Consultant Medical Microbiologist, University Hospitals of Leicester NHS Trust
  • Dr Duncan Wyncoll
    Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust
  • Alastair Bovell
    Senior Clinical Pharmacist based in London

Duration

1 Hr 30

FETCROJA ® (cefiderocol) Prescribing Information
Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents¹
▼ This medical product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Shionogi on 02030534190 or via contact@shionogi.eu

 

¹Fetcroja ® ▼ (cefiderocol) Summary of Product Characteristics https://www.medicines.org.uk/emc/product/11771/smpc#g

PP-UK-FDC-0630. February 2022.
Top

For UK healthcare professionals only*

These pages are not intended for patients or for members of the general public. These healthcare professional web pages contain promotional content.

 

I confirm that I am a healthcare professional* resident in the United Kingdom.

 

If you select ‘No’, you will be redirected to Shionogi.eu

 

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

 

PP-UK-FDC-0308. May 2021

Do you wish to continue?

You are now leaving www.talkinggramnegatives.com

 

PP-UK-FDC-0308. May 2021